Abstract
3
reported results on ClinicalTrials.gov. However, despite FDA public reporting requirements, up-to-date 77 study status information was often unavailable for 506B studies. 
103
Under the US Food and Drug Administration's (FDA) lifecycle evaluation process, it is assumed 104 that the benefit-risk balance of drugs and biologics will continue to be monitored after approval. [1, 2] 
105
Although FDA currently has four authorities that can be used to require New Drug Application (NDA) 106 sponsors (generally pharmaceutical companies) to conduct studies in the postmarket setting (i.e.,
107
"postmarketing requirements", Box 1),[3-5] additional clinical evidence, including long-term drug 108 effectiveness data, can be generated through "postmarketing commitments", which are "studies or clinical 109 trials that a sponsor has agreed to conduct, but that are not required by a statute or regulations". [5] 
110
Prior to 2008, the term "postmarketing commitment" referred to all required, agreed-upon, and 
119
For 506B studies, sponsors must annually report to the FDA the status of postmarketing commitments, 120 and the FDA must publicly report on the status of these commitments. [7] 121 Prior studies have focused exclusively on the characteristics, [8] 
166
Google searches using the terms "postmarketing requirement", "postmarketing commitment", "PMR", or
167
"PMC" in combination with the manufacturer or drug brand name to determine whether manufacturers
168
were publicly sharing their own information about postmarketing commitments (e.g., "Pfizer PMC" or 
244
All 16 postmarketing commitments outlining the completion or submission of results from 245 clinical trials were registered on ClinicalTrials.gov (Table 3) . Of these, 10 (62.5%) were randomized, 6 246 (37.5%) were double or triple blind, 6 (37.5%) were placebo controlled, and 4 (25.0%) had an active 247 comparator ( Table 4 ). The majority of the trials (10, 62.5%) focused on surrogate outcomes. According 248 to the ClinicalTrials.gov registrations, median study duration and estimated sample size were 5.6 months 249 (IQR, 5.2 to 12.6) and 237 patients (IQR, 373 to 744), respectively. 
250

330
Limitations of this study
331
This study has some limitations. First, by limiting our study to new approvals between 2009 and 332 2012, we did not identify and classify all postmarketing commitments issued after FDAAA. However, by 333 focusing on this time period, we allowed for at least four years for completion, results reporting, and 334 publication of postmarketing commitments. In our sample, the median study duration among clinical 335 trials was 1.6 months, and only one-quarter of clinical trials had durations longer than 12 months.
336
Therefore, we are reassured that our study allowed for an adequate amount of follow-up tome for studies 337 to be completed, reported, and published. Second, as previously discussed, our study was designed to rely 338 on publicly available data sources, which made determining study design characteristics,
339
ClinicalTrials.gov registrations, and corresponding publications difficult in some cases.
[8] Although we 340 attempted to be comprehensive by using numerous public data sources, we were unable to locate an up-341 to-date status for nearly half of the commitments. Therefore, it is possible that a number of commitments classified as "unclear" are actually "fulfilled" and "released" commitments, which are only displayed on 343 the FDA's online database for one year after the date of fulfillment or release. Third, we used the 344 milestone dates outlined in the initial FDA approval letters. However, sponsors can submit revised 345 schedules and FDA uses the original study schedule to determine study progress.
[13] Lastly, we also did 346 not account for the time that it might take to prepare and publish research. Although additional studies 347 could be published at a later date, but were not published at the time of our search, we based our decisions 348 on previous work by our group and others. [8, [28] [29] [30] [31] [32] 
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The datasets used and/or analysed during the current study are available from the corresponding author on 376 reasonable request (Joshua.wallach@yale.edu).
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